CSIMarket
 
Oragenics Inc   (OGEN)
Other Ticker:  
 
 
Price: $1.4000 $-0.04 -2.778%
Day's High: $1.49 Week Perf: -2.1 %
Day's Low: $ 1.40 30 Day Perf: -59.66 %
Volume (M): 35 52 Wk High: $ 7.74
Volume (M$): $ 48 52 Wk Avg: $3.47
Open: $1.49 52 Wk Low: $1.34



 Market Capitalization (Millions $) 3
 Shares Outstanding (Millions) 2
 Employees 14
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -12
 Cash Flow (TTM) (Millions $) -6
 Capital Exp. (TTM) (Millions $) 0

Oragenics Inc
Oragenics Inc is a bio-pharmaceutical company that is involved in the development of novel therapeutics for the treatment of infectious diseases. The company is headquartered in the United States, and its main focus is to create high-quality products to address major global health concerns.

Oragenics Inc's core technology is based on a proprietary platform called Oral Care and Therapeutics (OCAT). This platform is designed to develop drugs to tackle oral diseases by targeting the specific bacteria that are responsible for causing them. The OCAT platform uses recombinant DNA technology to generate beneficial microbes that can compete with and eradicate pathogenic bacteria.

The company's lead product candidate is TerraCoV2, which is a COVID-19 vaccine that uses its OCAT platform to develop a protein expression technology to generate recombinant spike proteins. This vaccine candidate is in preclinical development.

Oragenics Inc is also developing AG013, an oral mucositis treatment that uses the OCAT platform to generate a live biotherapeutic product that produces human tissue repair factors. This drug candidate is currently in Phase II clinical trials.

Another product candidate in the company's pipeline is OG716, which is an oral care product aimed at reducing the risk of dental caries. This product is a bacteriocin that uses the OCAT platform to generate a peptide that can selectively kill specific pathogenic bacteria without harming the beneficial bacteria.

In addition to its product development efforts, Oragenics Inc has established several partnerships with leading research institutions and pharmaceutical companies. These collaborations are focused on leveraging the company's technology and expertise to advance the development of disease vaccines, therapeutics, and diagnostic tools.

Overall, Oragenics Inc is a leading bio-pharmaceutical company that is dedicated to developing innovative products to address major global health concerns. With a strong pipeline of products and ongoing collaborations, the company is well-positioned to make a significant impact on the field of infectious disease therapeutics.


   Company Address: 4902 Eisenhower Blvd. Tampa 33634 FL
   Company Phone Number: 286-7900   Stock Exchange / Ticker: NYSE OGEN
   OGEN is expected to report next financial results on April 13, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Oragenics Inc

Oragenics Inc Faces Steep Decline and Industry Challenges In Second Quarter of 2023

Oragenics Inc, a major player in the pharmaceutical industry, recently announced a disastrous fiscal period with a significant decline in revenue and an expansion of net deficit per share. The company's revenue faded by a staggering -56.688% to just $0.01 million, while the net deficit per share expanded to $-1.51. This represents a significant setback compared to the corresponding reporting period from a year ago.
In contrast to Oragenics Inc's struggling performance, the rest of the Major Pharmaceutical Preparations sector has shown resilience and posted a 2.14% rise in top-line growth during the second quarter of 2023 compared to the same period in the previous year. This disparity highlights the challenges and difficulties faced by Oragenics Inc in a highly competitive industry.

Oragenics Inc

Oragenics Inc Achieves Impressive Revenue Growth despite Reporting Major Losses in Recent Fiscal Period

Oragenics Inc is a Major Pharmaceutical Preparations company founded in 1996. The company is focused on developing novel antibiotics for the treatment of diseases caused by infectious agents, as well as other areas of unmet medical needs.
Despite an increase in revenue of 12.869% from the corresponding financial reporting period a year before, Oragenics Inc reported a loss per share of $-1.41. This is a significant change from the preceding financial reporting period where the company reported earnings of $0.00 million and a loss per share of $-0.02. In the most recent fiscal period, the company reported a net loss of $-2.845 million, as opposed to a deficit of $-4.591 million in the corresponding financial reporting period a year before.






 

Oragenics Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com